Wednesday, 31 May 2023

Report 72: “Other AESIs” Included MERS, Multiple Organ Dysfunction Syndrome (MODS), Herpes Infections, and 96 DEATHS. 15 Patients Were Under Age 12, Including Six Infants.

May 30, 2023 • by Joseph Gehrett, MD; Barbara Gehrett, MD; Chris Flowers, MD; and Loree Britt

The War Room/DailyClout Pfizer Documents Analysis Project Post-Marketing Group (Team 1) – Joseph Gehrett, MD; Barbara Gehrett, MD; Chris Flowers, MD; and Loree Britt – wrote a report about Other Adverse Events of Special Interest (AESIs) found in Pfizer document 5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-FEB-2021 (a.k.a., “5.3.6“). This category of AESIs is not related to a specific set of medical conditions or a specific organ. Rather, it contains medical conditions such as herpes virus infections, MERS (Middle East Respiratory Syndrome), MODS (Multiple Organ Dysfunction Syndrome); symptoms such as fever and inflammation; and non-medical-related issues like manufacturing issues.

It is important to note that the AESIs in the 5.3.6 document were reported to Pfizer for only a 90-day period starting on December 1, 2020, the date of the United Kingdom’s public rollout of Pfizer’s COVID-19 experimental mRNA “vaccine” product.

Key points of this report include:

Death was listed as the “relevant [adverse] event outcome” for 96 individuals in this category.
Fifteen patients were under 12 years of age, including six infants; and Pfizer’s mRNA “vaccine” was not approved for use in people under age 16 at the time of 5.3.6‘s data collection.
Of those reports with gender known, 76% were female and 24% were male, a greater than 3:1 female to male ratio.
There were 391 herpes infectionsreported, including shingles, herpetic eye infections, and non-shingles herpes infections.
There were 18 Multiple Organ Dysfunction (MODS) adverse events.
Onset of adverse events, a.k.a. latency, was from within 24 hours to 61 days with half occurring within one day.
This category included 8,152 patients/cases, which is 19.4% of the total cases reported to Pfizer during its 90-day post-marketing safety surveillance.
Non-elderly adults had almost six times the number of adverse events seen in elderly adults.
Fever was the most common adverse event.
Pfizer concluded: “This cumulative case review does not raise new safety issues. Surveillance will continue.” To date, no follow-up, updated, and comprehensive safety report has been publicly released.